NASDAQ:ITCI
Intra-Cellular Therapies Inc. Stock News
$65.00
-1.53 (-2.30%)
At Close: May 17, 2024
Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes
08:30am, Tuesday, 19'th Mar 2024
NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ner
Intra-Cellular Therapies Is On Fire
07:11pm, Monday, 11'th Mar 2024
Intra-Cellular Therapies' flagship drug, CAPLYTA, saw a 63% increase in the number of psychiatrists prescribing it in 2023. The company is seeking FDA approval to expand CAPLYTA's use to treat Major D
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
08:00am, Wednesday, 06'th Mar 2024
NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ner
Intra-Cellular Therapies to Present at the 44th Annual TD Cowen Health Care Conference
08:00am, Tuesday, 27'th Feb 2024
NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv
Intra-Cellular (ITCI) Q4 Loss Narrower Than Expected, Sales Miss
09:46am, Friday, 23'rd Feb 2024
Intra-Cellular (ITCI) reports mixed fourth-quarter 2023 results despite Caplyta sales rising year over year on the back of increasing prescription trends.
3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition
10:08pm, Wednesday, 21'st Feb 2024
Now that the FED is looking to lower interest rates this year, cheaper money and more accessible financing will let investors venture into riskier places in the economy and the stock market. While not
Biotech/Drug Stocks Q4 Earnings Due Feb 22: MRNA, BHC, NTLA, BMRN & More
10:16am, Wednesday, 21'st Feb 2024
Let us take a look at what's in store for biotech/drug stocks MRNA, BHC, NTLA, BMRN and ITCI, which are scheduled to report on Feb 22.
Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'
10:51pm, Saturday, 10'th Feb 2024
Intra-Cellular's share price has increased by 450% over a five-year period and over 50% in the past year. The company's success is attributed to its approved drug, Caplyta, which has driven significan
Intra-Cellular Therapies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
08:00am, Tuesday, 02'nd Jan 2024
NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv
3 Biotech Bull Cases To Consider In 2024 - And 2 Wildcard Recommendations
02:12pm, Friday, 29'th Dec 2023
The biotech sector is finishing 2023 on a high after a difficult couple of years, buoyed by Big Pharma M&A activity. The SPDR® S&P Biotech ETF has been soaring as a result of the M&A spree. Despite a
Intra-Cellular Therapies (ITCI) is a Great Momentum Stock: Should You Buy?
01:32pm, Tuesday, 19'th Dec 2023
Does Intra-Cellular Therapies (ITCI) have what it takes to be a top stock pick for momentum investors? Let's find out.
3 Biotech Stocks Most Wall Street Analysts Are Bullish About
10:31am, Monday, 18'th Dec 2023
Here we present three biotech stocks, CRSP, ITCI and DVAX, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024, backed by strong fundamentals.
The Right Play On Intra-Cellular Therapies
11:49am, Monday, 20'th Nov 2023
Intra-Cellular Therapies, Inc. is a mid-cap biopharmaceutical company focused on developing treatments for neuropsychiatric and neurological disorders. The company's commercial asset, Caplyta, has ach
Intra-Cellular's Caplyta Is Well On Its Way To Being A Mental Health Blockbuster
05:47am, Monday, 13'th Nov 2023
Intra-Cellular Therapies shows strong financial growth, driven by Caplyta sales, with improved operational efficiency and reduced net losses. Caplyta's success in schizophrenia and bipolar depression,
Intra-Cellular (ITCI) Q3 Earnings Top, Product Sales View Raised
01:32pm, Friday, 03'rd Nov 2023
Intra-Cellular (ITCI) third-quarter 2023 earnings and revenues beat estimates. Caplyta sales continue to drive growth.